Skip to Content

Abera Bioscience AB Ordinary Shares - Stock Quote ABERA

Rating as of

Morningstar's Abera Bioscience AB Ordinary Shares Stock Analysis

Valuation
Currency in
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price

PREMIUM

5-Star Price

PREMIUM

Economic Moat

PREMIUM

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Abera Bioscience AB Ordinary Shares's Company Profile

Business Description

Abera Bioscience AB is a platform and vaccine development company based on research in the medical, molecular, and microbiological fields. The company's mission is to develop vaccine candidates based on its novel vaccine delivery platform to late pre-clinical or early clinical phase.

Contact
Svetsarvagen 15
Solna, SE-17141, Sweden
T +46 720202473
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Mar 31, 2022
Fiscal Year End Feb 23, 2022
Stock Type
Employees 5